MK-3475-975/KEYNOTE-975

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Mar 31, 2021 → Oct 16, 2026

Cited window

Jun 22, 2022 → Oct 16, 2026

Retrieved

Oct 18, 2026

Title

A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)

Registry

NCT04210115

Study IDs

3475-975 · MK-3475-975 (MSD) · KEYNOTE-975 (MSD) · PHRR200210-002490 (PHRR) · 205261 (Japic-CTI) · 2022-501531-16-00 (EU CT) · U1111-1281-0822 (UTN) · 2019-002006-51

Sponsor

Merck Sharp & Dohme LLC

Design

Phase 3 · Interventional, randomized, parallel

Status

Completed

Enrollment

703 actual

Start

2020-02-28 actual

Primary completion

2026-01-21 actual

Primary endpoint

Event-free Survival (EFS)

Interventions

8 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –Out of scope: 18 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
• –79 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
• –Further source limits apply, so some matching discussion may be missing.
• –The sources reviewed are not a representative sample of HCP opinion, and multiple formats of one discussion do not represent independent agreement.
• –Some potentially relevant posts and a video were unavailable to read. Parts of several long discussions were not completely assessed, so additional relevant opinions may be missing.
• –Several treatment, histology and safety comments cannot be reliably assigned to a named speaker. A program roster, institutional reference or professional identifier does not resolve that uncertainty.
• –Professional information is incomplete for some named contributors. Daisuke Kotani's and Megan Lenihan's clinical roles are not confirmed for this edition; names and source attribution do not verify credentials.
• –The negative EFS statements relay sponsor announcements. No KEYNOTE-975 results publication, quantitative efficacy analysis, detailed subgroup analysis or comparative safety analysis is among the sources reviewed.
• –Earlier anticipatory comments and later announcement reactions come from different dates and contexts. Their sequence does not establish a change of mind or direct disagreement over detailed results.
• –Some transcript wording is unclear, including an overexpression qualifier in the adenocarcinoma discussion; the initial organ-preservation proposal is truncated.
• –Cross-disease analogies, other-study response figures, institutional experience and anecdotal tolerability observations are not KEYNOTE-975 outcomes.
• –No full protocol document or complete regulatory evidence is available here. Descriptions of prescribing labels and local treatment standards remain the contributors' accounts.
• –General CPS-scoring concerns do not establish inaccurate testing in KEYNOTE-975, and local historical reporting thresholds must not be substituted for trial criteria.

How reports are built and checked: Methods.

Last checked for new commentary Oct 18, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.